Loureirin BCAS# 119425-90-0 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 119425-90-0 | SDF | Download SDF |
| PubChem ID | 189670 | Appearance | White powder |
| Formula | C18H20O5 | M.Wt | 316.35 |
| Type of Compound | Chalcones | Storage | Desiccate at -20°C |
| Synonyms | 4'-Hydroxy 2,4,6-trimethoxydihydrochalcone | ||
| Solubility | DMSO : ≥ 150 mg/mL (474.16 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 1-(4-hydroxyphenyl)-3-(2,4,6-trimethoxyphenyl)propan-1-one | ||
| SMILES | COC1=CC(=C(C(=C1)OC)CCC(=O)C2=CC=C(C=C2)O)OC | ||
| Standard InChIKey | ZPFRAPVRYLGYEC-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C18H20O5/c1-21-14-10-17(22-2)15(18(11-14)23-3)8-9-16(20)12-4-6-13(19)7-5-12/h4-7,10-11,19H,8-9H2,1-3H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Loureirin B, a flavonoid extracted from Dracaena cochinchinensis, is an inhibitor of plasminogen activator inhibitor-1 (PAI-1), with an IC50 of 26.10 μM; Loureirin B also inhibits KATP, the phosphorylation of ERK and JNK, and has anti-diabetic activity.Loureirin B inhibits fibroblast proliferation and extracellular matrix deposition in hypertrophic scar via TGF-β/Smad pathway, loureirin B can suppress tetrodotoxin-sensitive (TTX-S) voltage-gated sodium currents in a dose-dependent way. |
| Targets | TGF-β/Smad | MMP(e.g.TIMP) | GLUT | Calcium Channel | PAI-1 | ERK | JNK |
| In vitro | Loureirin B inhibits fibroblast proliferation and extracellular matrix deposition in hypertrophic scar via TGF-β/Smad pathway.[Pubmed: 25683490]Exp Dermatol. 2015 May;24(5):355-60.The ethanolic extract of Resina Draconis (RDEE) has been reported beneficial to normal wound healing yielding more regularly arranged collagen fibres. Loureirin B, a major component in RDEE, has been supposed to be effective on the prevention and treatment of pathological scars.
Effects of dragon's blood resin and its component loureirin B on tetrodotoxin-sensitive voltage-gated sodium currents in rat dorsal root ganglion neurons.[Pubmed: 15493475]Sci China C Life Sci. 2004 Aug;47(4):340-8.Using whole-cell patch clamp technique on the membrane of freshly isolated dorsal root ganglion (DRG) neurons, the effects of dragon's blood resin and its important component Loureirin B on tetrodotoxin-sensitive (TTX-S) voltage-gated sodium currents were observed.
|
| Kinase Assay | Loureirin B, an essential component of Sanguis Draxonis, inhibits Kv1.3 channel and suppresses cytokine release from Jurkat T cells.[Pubmed: 25937895]Cell Biosci. 2014 Dec 12;4:78.Sanguis draxonis (SD), also known as "Dragon's Blood", is a traditional herb medicine that has been used to treat a variety of complications with unknown mechanisms. Recent studies show that SD displays immunosuppressive activities and improves symptoms of type I diabetes in animal models. However, the mechanisms underlying SD's immunosuppressive actions are not completely understood. The voltage-gated Kv1.3 channel plays a critical role in the pathogenesis of autoimmune diseases by regulating the functions of both T cells and B cells.
|
| Cell Research | Protective Effects of Loureirin B on Dysfunction of Pacreatic Islet β Cell Induced by Palmitate.[Reference: WebLink]Effect of loureirin B on proliferation and extracellular matrix secretion of rat hepatic stellate cells in vitro.[Reference: WebLink]Shandong Medical Journal, 2012, 52(13):7-9.To investigate the effects of Loureirin B on proliferation and extracellular matrix secretion of rat hepatic stellate cells in vitro.
Chinese Journal of Experimental Traditional Medical, 2013, 19(23):254-7.To study the protective effects and mechanism of Loureirin B on the dysfunctiion of pancreatic islet β cell induced by palmitic acid.
|
Loureirin B Dilution Calculator
Loureirin B Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.1611 mL | 15.8053 mL | 31.6106 mL | 63.2211 mL | 79.0264 mL |
| 5 mM | 0.6322 mL | 3.1611 mL | 6.3221 mL | 12.6442 mL | 15.8053 mL |
| 10 mM | 0.3161 mL | 1.5805 mL | 3.1611 mL | 6.3221 mL | 7.9026 mL |
| 50 mM | 0.0632 mL | 0.3161 mL | 0.6322 mL | 1.2644 mL | 1.5805 mL |
| 100 mM | 0.0316 mL | 0.1581 mL | 0.3161 mL | 0.6322 mL | 0.7903 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Loureirin B, a flavonoid extracted from Dracaena cochinchinensis, is an inhibitor of plasminogen activator inhibitor-1 (PAI-1), with an IC50 of 26.10 μM; Loureirin B also inhibits KATP, the phosphorylation of ERK and JNK, and has anti-diabetic activity.
In Vitro:Loureirin B enhances the relative mRNA level of Pdx-1 and MafA. Loureirin B (1, 0.1, and 0.01 µM) increases insulin secretion in Ins-1 cells. Loureirin B (0.01 µM) almost causes no toxicity on cells. Loureirin B improves the level of expressions of MafA and Pdx-1 and ATP level. Loureirin B inhibits the KATP current but increases the [Ca2+]i level in Ins-1 cells[1]. Loureirin B inhibits the expression of Col1 and FN, as well as the TGF-β1-mediated up regulation of p-JNK. Loureirin B also inhibits the up regulation of p-ERK that is induced by TGF-β1. Moreover, Loureirin B inhibits the contraction of TGF-β1-stimulated fibroblasts through the down regulation of p-ERK and p-JNK. However, Loureirin B does not suppress the up regulation of p-p38 that is induced by TGF-β1[2]. Loureirin B downregulates both mRNA and protein levels of type I collagen, type III collagen and α-smooth muscle actin in a dose dependent manner in HS fibroblasts. Loureirin B also suppresses fibroblast proliferative activity and redistributes cell cycle, but does not affect cell apoptosis[3].
In Vivo:Loureirin B significantly improves the arrangement and deposition of collagen fibres, decreases protein levels of ColI, ColIII and α-SMA and suppresses myofibroblast differentiation and scar proliferative activity, in a rabbit ear scar model. Loureirin B effectively inhibits TGF-β1-induced upregulation of ColI, ColIII and α-SMA levels, myofibroblast differentiation and the activation of Smad2 and Smad3, in NS fibroblasts[3].
References:
[1]. Sha Y, et al. Loureirin B promotes insulin secretion through inhibition of KATP channel and influx of intracellular calcium. J Cell Biochem. 2017 Aug 17.
[2]. He T, et al. Loureirin B Inhibits Hypertrophic Scar Formation via Inhibition of the TGF-β1-ERK/JNK Pathway. Cell Physiol Biochem. 2015;37(2):666-76.
[3]. Bai X, et al. Loureirin B inhibits fibroblast proliferation and extracellular matrix deposition in hypertrophic scar via TGF-β/Smad pathway. Exp Dermatol. 2015 May;24(5):355-60.
[4]. Yu Jiang, et al. Bioactivity-Guided Fractionation of the Traditional Chinese Medicine Resina Draconis Reveals Loureirin B as a PAI-1 Inhibitor. Evidence-Based Complementary and Alternative Medicine
- Loureirin A
Catalog No.:BCN3671
CAS No.:119425-89-7
- Galanin (1-30) (human)
Catalog No.:BCC6961
CAS No.:119418-04-1
- Licoricesaponin E2
Catalog No.:BCN7894
CAS No.:119417-96-8
- Topotecan hydrochloride
Catalog No.:BCN2604
CAS No.:119413-54-6
- LY2811376
Catalog No.:BCC2102
CAS No.:1194044-20-6
- Przewalskin
Catalog No.:BCN6080
CAS No.:119400-87-2
- Salviolone
Catalog No.:BCN3141
CAS No.:119400-86-1
- 2,5-Dihydroxybenzaldehyde
Catalog No.:BCN6081
CAS No.:1194-98-5
- mAChR-IN-1
Catalog No.:BCC5512
CAS No.:119391-56-9
- 2-Deacetoxytaxinine J
Catalog No.:BCN7291
CAS No.:119347-14-7
- CRANAD 2
Catalog No.:BCC6293
CAS No.:1193447-34-5
- 2-Hydroxydiplopterol
Catalog No.:BCN7290
CAS No.:1193250-54-2
- Eliprodil
Catalog No.:BCC7280
CAS No.:119431-25-3
- Fruquintinib(HMPL-013)
Catalog No.:BCC6415
CAS No.:1194506-26-7
- Meropenem trihydrate
Catalog No.:BCC4226
CAS No.:119478-56-7
- Ethyllucidone
Catalog No.:BCN6082
CAS No.:1195233-59-0
- Ceanothic acid acetate
Catalog No.:BCN6083
CAS No.:119533-63-0
- Othonnine
Catalog No.:BCN2061
CAS No.:119565-25-2
- N,N-Dimethylsphingosine
Catalog No.:BCC7959
CAS No.:119567-63-4
- 11-Hydroxygelsenicine
Catalog No.:BCN4761
CAS No.:1195760-68-9
- Dabrafenib (GSK2118436)
Catalog No.:BCC4393
CAS No.:1195765-45-7
- Dabrafenib Mesylate (GSK-2118436)
Catalog No.:BCC1513
CAS No.:1195768-06-9
- 7-Ethyl-10-Hydroxy-Camptothecin
Catalog No.:BCN8386
CAS No.:119577-28-5
- 2-Hydroxyquinoxaline
Catalog No.:BCC8577
CAS No.:1196-57-2
Loureirin B, an essential component of Sanguis Draxonis, inhibits Kv1.3 channel and suppresses cytokine release from Jurkat T cells.[Pubmed:25937895]
Cell Biosci. 2014 Dec 12;4:78.
Sanguis draxonis (SD), also known as "Dragon's Blood", is a traditional herb medicine that has been used to treat a variety of complications with unknown mechanisms. Recent studies show that SD displays immunosuppressive activities and improves symptoms of type I diabetes in animal models. However, the mechanisms underlying SD's immunosuppressive actions are not completely understood. The voltage-gated Kv1.3 channel plays a critical role in the pathogenesis of autoimmune diseases by regulating the functions of both T cells and B cells. Here we investigated the effect of SD and one of its active components Loureirin B (LrB) on Kv1.3. Both SD and LrB inhibited Kv1.3-mediated currents, produced a membrane depolarization, and reduced Ca(2+) influx in Jurkat T cells. In addition, application of LrB inhibited phytohemagglutinin (PHA)-induced IL-2 release from activated Jurkat T cells. Furthermore, point mutations in the selective filter region significantly reduced the inhibitory effect of LrB on Kv1.3. The results of these experiments provide evidence that LrB is a channel blocker of Kv1.3 by interacting with amino acid residues in its selective filter region. Direct inhibition of Kv1.3 in T cells by SD and LrB might be the cellular and molecular basis of SD-mediated immunosuppression.
Effects of dragon's blood resin and its component loureirin B on tetrodotoxin-sensitive voltage-gated sodium currents in rat dorsal root ganglion neurons.[Pubmed:15493475]
Sci China C Life Sci. 2004 Aug;47(4):340-8.
Using whole-cell patch clamp technique on the membrane of freshly isolated dorsal root ganglion (DRG) neurons, the effects of dragon's blood resin and its important component Loureirin B on tetrodotoxin-sensitive (TTX-S) voltage-gated sodium currents were observed. The results show that both blood resin and Loureirin B could suppress TTX-S voltage-gated sodium currents in a dose-dependent way. The peak current amplitudes and the steady-state activation and inactivation curves are also made to shift by 0.05% blood resin and 0.2 mmol/L Loureirin B. These results demonstrate that the effects of blood resin on TTX-S sodium current may contribute to Loureirin B in blood resin. Perhaps the analgesic effect of blood resin is caused partly by Loureirin B directly interfering with the nociceptive transmission of primary sensory neurons.
Loureirin B inhibits fibroblast proliferation and extracellular matrix deposition in hypertrophic scar via TGF-beta/Smad pathway.[Pubmed:25683490]
Exp Dermatol. 2015 May;24(5):355-60.
The ethanolic extract of Resina Draconis (RDEE) has been reported beneficial to normal wound healing yielding more regularly arranged collagen fibres. Loureirin B, a major component in RDEE, has been supposed to be effective on the prevention and treatment of pathological scars. To investigate the therapeutic effects of Loureirin B on hypertrophic scar (HS), fibroblasts from human HS and normal skin (NS) were isolated. Results showed that Loureirin B dose-dependently downregulated both mRNA and protein levels of type I collagen (ColI), type III collagen (ColIII) and alpha-smooth muscle actin (alpha-SMA) in HS fibroblasts. Loureirin B also suppressed fibroblast proliferative activity and redistributed cell cycle, but did not affect cell apoptosis. In vivo rabbit ear scar model, Loureirin B significantly improved the arrangement and deposition of collagen fibres, decreased protein levels of ColI, ColIII and alpha-SMA and suppressed myofibroblast differentiation and scar proliferative activity. In NS fibroblasts, Loureirin B effectively inhibited TGF-beta1-induced upregulation of ColI, ColIII and alpha-SMA levels, myofibroblast differentiation and the activation of Smad2 and Smad3. Loureirin B also affected mRNA levels of major MMPs and TIMPs in TGF-beta1-stimulated fibroblasts. Taken together, this study demonstrates that Loureirin B could downregulate the expression of fibrosis-related molecules by regulating MMPs and TIMPs levels, inhibit scar fibroblast proliferation and suppress TGF-beta1-induced fibrosis, during which TGF-beta1/Smad2/3 pathway is likely involved. These findings suggest that Loureirin B is a potential therapeutic compound for HS treatment.
